Dutch microRNA drug developer InteRNA Technologies this month announced that it has received a notice of allowance from the US Patent and Trademark Office for a patent application covering a number of novel microRNA sequences, including one that forms the basis of the company's lead drug candidate.

With the intellectual property in hand, InteRNA has now set its sights on raising additional capital and advancing at least one therapeutic into human testing by the end of 2013, a company official told Gene Silencing News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.